Loading
institutionsInstitution
Kindai University Faculty of Medicine and Hospital
Osaka-area university hospital whose gastroenterology and hepatology department, under Masatoshi Kudo, has led many of the global trials of liver cancer drugs, including REFLECT of lenvatinib.
Also called: Kindai UniversityKinki University近畿大学医学部
Overview
Kindai University's Faculty of Medicine and its hospital in Osakasayama, south of Osaka, run one of Japan's largest hepatocellular carcinoma programmes. The Department of Gastroenterology and Hepatology, chaired by Masatoshi Kudo, was the lead centre for REFLECT, the 2018 Lancet trial that showed lenvatinib was non-inferior to sorafenib in unresectable liver cancer, and has led or co-led the trials of atezolizumab-bevacizumab, durvalumab-tremelimumab and transarterial therapies. The faculty also has a strong medical oncology department in lung cancer.
Location
Osakasayama, Osaka, JP
Type
hospital · Kindai University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#686 · 2 points (0 Newsweek + 0 NCI + 2 from 1 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Kindai University, including child institutions. 658 works · 6,074 citations · 79% open access · 18% clinical trials · 1% reviews.
Oncology works per year
1252022
1532023
1192024
1582025
1032026
Most works
- Masatoshi Kudo58 works
- Hisato Kawakami46 works
- Hidetoshi Hayashi42 works
- Kazuhiko Nakagawa39 works
- Noriomi Matsumura30 works
- Kazuto Nishio29 works
- Seiichiro Mitani28 works
- Yasutaka Chiba26 works
- Kazuko Sakai25 works
- Mamoru Takenaka25 works
Most cited
- Hepatocellular carcinoma trials
- Interventional hepatology
- Thoracic oncology
Similar pages
- TrialREFLECT
Shares Masatoshi Kudo, Hepatocellular carcinoma.